about
The role of observational studies in optimizing the clinical management of chronic myeloid leukemiaReduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS).Effectiveness of triple therapy with direct-acting antivirals for hepatitis C genotype 1 infection: application of propensity score matching in a national HCV treatment registry.Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays.Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS)Osteoporosis therapies: evidence from health-care databases and observational population studies.Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice.Fracture Incidence, Quality of Life, and Back Pain during 18-Months Treatment with Teriparatide in Greek Postmenopausal Women with Osteoporosis: Results from the European Forsteo Observational StudyEffectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort studyEffects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational StudyCharacteristics associated with bone mineral density responses to alendronate in men.Risedronate for prevention and treatment of osteoporosis in postmenopausal women.Risk factors for treatment failure with antiosteoporosis medication: the global longitudinal study of osteoporosis in women (GLOW).Role of observational studies in assessing osteoporosis therapies: the REAL study.A systematic literature review on the efficacy-effectiveness gap: comparison of randomized controlled trials and observational studies of glucose-lowering drugs.Monitoring pharmacological therapy for osteoporosis.Improving adherence in osteoporosis: a new management algorithm for the patient with osteoporosis.Systematic literature review of clinical trials evaluating pharmacotherapy for overactive bladder in elderly patients: An assessment of trial quality.Time trends in osteoporosis risk factor profiles: a comparative analysis of risk factors, comorbidities, and medications over twelve years.Comparing clinical and economic outcomes of biologic and conventional medications in postmenopausal women with osteoporosis.Persistence to medical treatment of osteoporosis in women at three different clinical settings--a historical cohort study.Teriparatide treatment of severe osteoporosis reduces the risk of vertebral fractures compared with standard care in routine clinical practice.Participation of older people in preauthorization trials of recently approved medicines.Real-world effectiveness of daily teriparatide in Japanese patients with osteoporosis at high risk for fracture: final results from the 24-month Japan Fracture Observational Study (JFOS).Design of a randomized clinical trial of concurrent treatment with vitamin K2 and risedronate compared to risedronate alone in osteoporotic patients: Japanese Osteoporosis Intervention Trial-03 (JOINT-03).Improved real-life adherence of 6-monthly denosumab injections due to positive feedback based on rapid 6-month BMD increase and good safety profile.Les bisphosphonates dans le traitement de l’ostéoporose: Bienfaits attendus, torts potentiels et congés thérapeutiques.The Challenges and Opportunities of Pharmacoepidemiology in Bone Diseases
P2860
Q28085149-6C47FA4F-6540-4FE0-B95A-75C22FBC448FQ33510168-4C400103-51A2-4ABF-8813-331EB0351571Q33576871-0B7AD676-43DA-4136-8585-67D330E0865BQ33715141-F755C6BE-C189-4B44-8901-A1D0BA4BDE45Q33757516-844B9878-BA50-417F-9655-1F83ECF118B4Q34242906-BDA9B077-C951-4D34-BC5A-661E94AEBE04Q34645740-9706CE82-718B-4851-BBC8-7D39F9B16008Q35222686-73BB276B-BAA9-4CE4-92C5-6CB7D5D3FF9AQ35230210-E52BE67C-3510-4D8F-AE50-CD720F0A53A8Q35598005-825F7131-1425-4140-9680-9094FA84FC04Q36029011-32070EF9-616F-4F02-A6CF-5B43CF7FFFCCQ36082078-7FC1180B-6100-415C-B770-BA529922F18DQ36930096-FC392B1E-8B0C-4C7B-9AAE-018B881FD44AQ37430500-9438F756-6076-4AA8-9625-6085447EFC89Q37610459-51EC82D0-8880-499B-B026-8559A4166F7EQ37689559-A2D7FE5F-587F-4CA0-9CBE-375C5C10D597Q37827874-969FA84B-00CE-4E44-8329-FD0C48DBEA9CQ38648674-2A04E673-BC95-4C08-BBF2-643700E9C4A4Q39767213-D1D3F649-132F-4765-859F-FF21FE73B136Q40852576-2611D25A-C079-4471-A4AC-88B44FEBDB66Q43059573-3E3BE4B1-C657-445E-A080-DDC34C2C1B41Q45157687-DC5F40E3-338C-477B-B275-E9ACAB666195Q45395709-D6C66FD6-84D5-4A3E-BE59-0C4A3240B35BQ47701411-69910C5B-2F57-47DB-BED3-45267C7E4C38Q50701939-8B1A4336-E689-4F71-A085-74033EE6BF85Q50764107-A107B4E9-F672-4786-9D93-18A5EAFB686AQ55452474-D8283D89-E9A3-4399-B1C2-00E6E1069EA6Q57145898-EB0544AA-5C5A-494B-9DC7-654C3534A327
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Study subjects and ordinary patients.
@ast
Study subjects and ordinary patients.
@en
Study subjects and ordinary patients.
@nl
type
label
Study subjects and ordinary patients.
@ast
Study subjects and ordinary patients.
@en
Study subjects and ordinary patients.
@nl
prefLabel
Study subjects and ordinary patients.
@ast
Study subjects and ordinary patients.
@en
Study subjects and ordinary patients.
@nl
P2093
P356
P1476
Study subjects and ordinary patients.
@en
P2093
P2888
P304
P356
10.1007/S001980070097
P407
P577
2000-01-01T00:00:00Z
P6179
1029162607